伊那鲁单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | B细胞激活因子 |
| 臨床資料 | |
| 其他名稱 | VAY736、伊利尤单抗 |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1929549-92-7 |
| UNII | |
| KEGG | |
伊那鲁单抗（INN：ianalumab；开发代号：VAY736），或译伊利尤单抗，是一种单克隆抗体，正在被研究用于治疗自身免疫性肝炎、多发性硬化症、寻常型天疱疮、类风湿性关节炎、干燥综合征和系统性红斑狼疮。[1][2][3]
该药物由诺华公司开发。2021年，伊那鲁单抗正在进行II/III期试验。[4][5]2023年6月伊那鲁单抗参与了22项临床试验，其中3项已完成，14项正在进行，1项计划中，4项终止。[6]
参考资料
[编辑]- ^ Ianalumab - MorphoSys/Novartis. AdisInsight. Springer Nature Switzerland AG. [2024-05-25]. （原始内容存档于2021-08-10）.
- ^ van den Hoogen LL, van Laar JM. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. Best Practice & Research. Clinical Rheumatology. February 2020, 34 (1): 101485. PMID 32067925. doi:10.1016/j.berh.2020.101485
.
- ^ Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Current Opinion in Rheumatology. November 2020, 32 (6): 609–616. PMID 33002950. S2CID 222150641. doi:10.1097/BOR.0000000000000754.
- ^ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
- ^ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
- ^ Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab. Pharmaceutical Technology. 30 June 2023 [2024-05-25]. （原始内容存档于2023-09-23）.
